Clinical Applications of Circulating Tumor Cells and Circulating Tumor DNA as Liquid Biopsy

Pantel, 2010, Circulating tumour cells in cancer patients: challenges and perspectives, Trends Mol Med, 16, 398, 10.1016/j.molmed.2010.07.001

Diaz, 2014, Liquid biopsies: genotyping circulating tumor DNA, J Clin Oncol, 32, 579, 10.1200/JCO.2012.45.2011

Haber, 2014, Blood-based analyses of cancer: circulating tumor cells and circulating tumor DNA, Cancer Discov, 4, 650, 10.1158/2159-8290.CD-13-1014

Pantel, 2013, Real-time liquid biopsy in cancer patients: fact or fiction?, Cancer Res, 73, 6384, 10.1158/0008-5472.CAN-13-2030

Meng, 2004, Circulating tumor cells in patients with breast cancer dormancy, Clin Cancer Res, 10, 8152, 10.1158/1078-0432.CCR-04-1110

Kang, 2013, Tumor cell dissemination: emerging biological insights from animal models and cancer patients, Cancer Cell, 23, 573, 10.1016/j.ccr.2013.04.017

Larson, 2004, Apoptosis of circulating tumor cells in prostate cancer patients, Cytometry A, 62, 46, 10.1002/cyto.a.20073

Deneve, 2013, Capture of viable circulating tumor cells in the liver of colorectal cancer patients, Clin Chem, 59, 1384, 10.1373/clinchem.2013.202846

Smith, 2013, The metastasis-promoting roles of tumor-associated immune cells, J Mol Med (Berl), 91, 411, 10.1007/s00109-013-1021-5

Gay, 2011, Contribution of platelets to tumour metastasis, Nat Rev Cancer, 11, 123, 10.1038/nrc3004

Bonecchi, 2009, Chemokines and chemokine receptors: an overview, Front Biosci (Landmark Ed), 14, 540, 10.2741/3261

Muller, 2005, Circulating tumor cells in breast cancer: correlation to bone marrow micrometastases, heterogeneous response to systemic therapy and low proliferative activity, Clin Cancer Res, 11, 3678, 10.1158/1078-0432.CCR-04-2469

Kim, 2009, Tumor self-seeding by circulating cancer cells, Cell, 139, 1315, 10.1016/j.cell.2009.11.025

Braun, 2005, A pooled analysis of bone marrow micrometastasis in breast cancer, N Engl J Med, 353, 793, 10.1056/NEJMoa050434

Alix-Panabieres, 2014, Challenges in circulating tumour cell research, Nat Rev Cancer, 14, 623, 10.1038/nrc3820

Mani, 2008, The epithelial–mesenchymal transition generates cells with properties of stem cells, Cell, 133, 704, 10.1016/j.cell.2008.03.027

Tam, 2013, The epigenetics of epithelial–mesenchymal plasticity in cancer, Nat Med, 19, 1438, 10.1038/nm.3336

Cayrefourcq, 2015, Establishment and characterization of a cell line from human circulating colon cancer cells, Cancer Res, 75, 892, 10.1158/0008-5472.CAN-14-2613

Baccelli, 2013, Identification of a population of blood circulating tumor cells from breast cancer patients that initiates metastasis in a xenograft assay, Nat Biotechnol, 31, 539, 10.1038/nbt.2576

Kahlert, 2014, Identification of double-stranded genomic DNA spanning all chromosomes with mutated KRAS and p53 DNA in the serum exosomes of patients with pancreatic cancer, J Biol Chem, 289, 3869, 10.1074/jbc.C113.532267

Thakur, 2014, Double-stranded DNA in exosomes: a novel biomarker in cancer detection, Cell Res, 24, 766, 10.1038/cr.2014.44

Heitzer, 2013, Establishment of tumor-specific copy number alterations from plasma DNA of patients with cancer, Int J Cancer, 133, 346, 10.1002/ijc.28030

Lo, 1999, Rapid clearance of fetal DNA from maternal plasma, Am J Hum Genet, 64, 218, 10.1086/302205

Elshimali, 2013, The clinical utilization of circulating cell free DNA (CCFDNA) in blood of cancer patients, Int J Mol Sci, 14, 18925, 10.3390/ijms140918925

Kirsch, 2008, An improved method for the isolation of free-circulating plasma DNA and cell-free DNA from other body fluids, Ann N Y Acad Sci, 1137, 135, 10.1196/annals.1448.035

Schwarzenbach, 2011, Cell-free nucleic acids as biomarkers in cancer patients, Nat Rev Cancer, 11, 426, 10.1038/nrc3066

Trejo-Becerril, 2012, Cancer progression mediated by horizontal gene transfer in an in vivo model, PLoS One, 7, e52754, 10.1371/journal.pone.0052754

De Lamirande, 1961, Action of deoxyribonuclease and ribonuclease on the growth of Ehrlich ascites carcinoma in mice, Nature, 192, 52, 10.1038/192052a0

Pantel, 2016, Functional Studies on Viable Circulating Tumor Cells, Clin Chem, 62, 328, 10.1373/clinchem.2015.242537

Alix-Panabieres, 2015, Liquid biopsy in cancer patients: advances in capturing viable CTCs for functional studies using the EPISPOT assay, Expert review of molecular diagnostics, 15, 1411, 10.1586/14737159.2015.1091729

Pantel, 2015, The biology of circulating tumor cells, Oncogene

Murtaza, 2013, Non-invasive analysis of acquired resistance to cancer therapy by sequencing of plasma DNA, Nature, 497, 108, 10.1038/nature12065

Heitzer, 2015, Circulating tumor DNA as a liquid biopsy for cancer, Clin Chem, 61, 112, 10.1373/clinchem.2014.222679

Newman, 2014, An ultrasensitive method for quantitating circulating tumor DNA with broad patient coverage, Nat Med, 20, 548, 10.1038/nm.3519

Ilie, 2014, "Sentinel" circulating tumor cells allow early diagnosis of lung cancer in patients with chronic obstructive pulmonary disease, PLoS One, 9, e111597, 10.1371/journal.pone.0111597

Pantel, 2012, Circulating epithelial cells in patients with benign colon diseases, Clin Chem, 58, 936, 10.1373/clinchem.2011.175570

Yong, 2014, Cancer biomarkers: written in blood, Nature, 511, 524, 10.1038/511524a

Spellman, 2014, Detecting cancer by monitoring circulating tumor DNA, Nat Med, 20, 474, 10.1038/nm.3564

Bettegowda, 2014, Detection of circulating tumor DNA in early- and late-stage human malignancies, Sci Transl Med, 6, 224ra24, 10.1126/scitranslmed.3007094

Genovese, 2014, Clonal hematopoiesis and blood-cancer risk inferred from blood DNA sequence, N Engl J Med, 371, 2477, 10.1056/NEJMoa1409405

Zhang, 2012, Meta-analysis of the prognostic value of circulating tumor cells in breast cancer, Clin Cancer Res, 18, 5701, 10.1158/1078-0432.CCR-12-1587

Rack, 2014, Circulating tumor cells predict survival in early average-to-high risk breast cancer patients, J Natl Cancer Inst, 106

Loh, 2014, Circulating tumor cell detection in high-risk non-metastatic prostate cancer, J Cancer Res Clin Oncol, 140, 2157, 10.1007/s00432-014-1775-3

Thalgott, 2015, Detection of Circulating Tumor Cells in Locally Advanced High-risk Prostate Cancer During Neoadjuvant Chemotherapy and Radical Prostatectomy, Anticancer Res, 35, 5679

Rink, 2012, Prognostic role and HER2 expression of circulating tumor cells in peripheral blood of patients prior to radical cystectomy: a prospective study, Eur Urol, 61, 810, 10.1016/j.eururo.2012.01.017

Gazzaniga, 2014, Circulating tumor cells detection has independent prognostic impact in high-risk non-muscle invasive bladder cancer, Int J Cancer, 135, 1978, 10.1002/ijc.28830

Schulze, 2013, Presence of EpCAM-positive circulating tumor cells as biomarker for systemic disease strongly correlates to survival in patients with hepatocellular carcinoma, Int J Cancer, 133, 2165, 10.1002/ijc.28230

Vashist, 2012, Disseminated tumor cells in bone marrow and the natural course of resected esophageal cancer, Ann Surg, 255, 1105, 10.1097/SLA.0b013e3182565b0b

Goss, 2010, Does tumour dormancy offer a therapeutic target?, Nat Rev Cancer, 10, 871, 10.1038/nrc2933

Shaw, 2012, Genomic analysis of circulating cell-free DNA infers breast cancer dormancy, Genome Res, 22, 220, 10.1101/gr.123497.111

Bosch, 2015, PI3K inhibition results in enhanced estrogen receptor function and dependence in hormone receptor–positive breast cancer, Sci Transl Med, 7, 283ra51, 10.1126/scitranslmed.aaa4442

Oshiro, 2015, PIK3CA mutations in serum DNA are predictive of recurrence in primary breast cancer patients, Breast cancer research and treatment, 150, 299, 10.1007/s10549-015-3322-6

Reinert, 2015 4, Analysis of circulating tumour DNA to monitor disease burden following colorectal cancer surgery, Gut, pii

Tie, 2015, Circulating tumor DNA as an early marker of therapeutic response in patients with metastatic colorectal cancer, Ann Oncol, 26, 1715, 10.1093/annonc/mdv177

Babayan, 2013, Heterogeneity of estrogen receptor expression in circulating tumor cells from metastatic breast cancer patients, PLoS One, 8, e75038, 10.1371/journal.pone.0075038

Paoletti, 2015, Development of circulating tumor cell-endocrine therapy index in patients with hormone receptor-positive breast cancer, Clin Cancer Res, 21, 2487, 10.1158/1078-0432.CCR-14-1913

Fehm, 2010, HER2 status of circulating tumor cells in patients with metastatic breast cancer: a prospective, multicenter trial, Breast Cancer Res Treat, 124, 403, 10.1007/s10549-010-1163-x

Riethdorf, 2010, Detection and HER2 Expression of Circulating Tumor Cells: Prospective Monitoring in Breast Cancer Patients Treated in the Neoadjuvant GeparQuattro Trial, Clin Cancer Res, 16, 2634, 10.1158/1078-0432.CCR-09-2042

Ignatiadis, 2011, HER2-positive circulating tumor cells in breast cancer, PLoS One, 6, e15624, 10.1371/journal.pone.0015624

Philips, 2015, Therapeutic uses of anti-PD-1 and anti-PD-L1 antibodies, Int Immunol, 27, 39, 10.1093/intimm/dxu095

Mazel, 2015, Frequent expression of PD-L1 on circulating breast cancer cells, Mol Oncol, 9, 1773, 10.1016/j.molonc.2015.05.009

David, 2015, PD-L1 expression by circulating breast cancer cells, Lancet Oncol, 16, e321, 10.1016/S1470-2045(15)00074-1

Miyamoto, 2012, Androgen receptor signaling in circulating tumor cells as a marker of hormonally responsive prostate cancer, Cancer Discov, 2, 995, 10.1158/2159-8290.CD-12-0222

Lianidou, 2011, Circulating tumor cells in breast cancer: detection systems, molecular characterization, and future challenges, Clin Chem, 57, 1242, 10.1373/clinchem.2011.165068

Gillessen, 2015, Management of patients with advanced prostate cancer: recommendations of the St Gallen Advanced Prostate Cancer Consensus Conference (APCCC) 2015, Ann Oncol, 26, 1589, 10.1093/annonc/mdv257

Antonarakis, 2014, AR-V7 and resistance to enzalutamide and abiraterone in prostate cancer, N Engl J Med, 371, 1028, 10.1056/NEJMoa1315815

Steinestel, 2015 23, Detecting predictive androgen receptor modifications in circulating prostate cancer cells, Oncotarget

Thadani-Mulero, 2014, Androgen receptor splice variants determine taxane sensitivity in prostate cancer, Cancer Res, 74, 2270, 10.1158/0008-5472.CAN-13-2876

Antonarakis, 2015, Androgen Receptor Splice Variant 7 and Efficacy of Taxane Chemotherapy in Patients With Metastatic Castration-Resistant Prostate Cancer, JAMA oncology, 1, 582, 10.1001/jamaoncol.2015.1341

Nakazawa, 2015, Serial blood-based analysis of AR-V7 in men with advanced prostate cancer, Ann Oncol, 26, 1859, 10.1093/annonc/mdv282

Onstenk, 2015, Efficacy of Cabazitaxel in Castration-resistant Prostate Cancer Is Independent of the Presence of AR-V7 in Circulating Tumor Cells, Eur Urol, 68, 939, 10.1016/j.eururo.2015.07.007

Miyamoto, 2015, RNA-Seq of single prostate CTCs implicates noncanonical Wnt signaling in antiandrogen resistance, Science, 349, 1351, 10.1126/science.aab0917

Gasch, 2015, Heterogeneity of miR-10b expression in circulating tumor cells, Scientific reports, 5, 15980, 10.1038/srep15980

Gasch, 2013, Heterogeneity of epidermal growth factor receptor status and mutations of KRAS/PIK3CA in circulating tumor cells of patients with colorectal cancer, Clin Chem, 59, 252, 10.1373/clinchem.2012.188557

Mostert, 2013, KRAS and BRAF mutation status in circulating colorectal tumor cells and their correlation with primary and metastatic tumor tissue, Int J Cancer, 133, 130, 10.1002/ijc.27987

Jiang, 2010, Detection of androgen receptor mutations in circulating tumor cells in castration-resistant prostate cancer, Clin Chem, 56, 1492, 10.1373/clinchem.2010.143297

Mukohara, 2011, Mechanisms of resistance to anti-human epidermal growth factor receptor 2 agents in breast cancer, Cancer Sci, 102, 1, 10.1111/j.1349-7006.2010.01711.x

Ibrahim, 2015, The predictive and prognostic role of phosphatase phosphoinositol-3 (PI3) kinase (PIK3CA) mutation in HER2-positive breast cancer receiving HER2-targeted therapy: a meta-analysis, Breast Cancer Res Treat, 152, 463, 10.1007/s10549-015-3480-6

Mukohara, 2015, PI3K mutations in breast cancer: prognostic and therapeutic implications, Breast Cancer (Dove Med Press), 7, 111

Schneck, 2013, Analysing the mutational status of PIK3CA in circulating tumor cells from metastatic breast cancer patients, Mol Oncol, 7, 976, 10.1016/j.molonc.2013.07.007

Neves, 2014, Genomic high-resolution profiling of single CKpos/CD45neg flow-sorting purified circulating tumor cells from patients with metastatic breast cancer, Clin Chem, 60, 1290, 10.1373/clinchem.2014.222331

Pestrin, 2015, Heterogeneity of PIK3CA mutational status at the single cell level in circulating tumor cells from metastatic breast cancer patients, Mol Oncol, 9, 749, 10.1016/j.molonc.2014.12.001

Polzer, 2014, Molecular profiling of single circulating tumor cells with diagnostic intention, EMBO Mol Med, 6, 1371, 10.15252/emmm.201404033

Sakaizawa, 2012, Mutation analysis of BRAF and KIT in circulating melanoma cells at the single cell level, Br J Cancer, 106, 939, 10.1038/bjc.2012.12

Luo, 2014, Isolation and molecular characterization of circulating melanoma cells, Cell Reports, 7, 645, 10.1016/j.celrep.2014.03.039

Heitzer, 2013, Complex tumor genomes inferred from single circulating tumor cells by array-CGH and next-generation sequencing, Cancer Res, 73, 2965, 10.1158/0008-5472.CAN-12-4140

Peyressatre, 2015, Targeting cyclin-dependent kinases in human cancers: from small molecules to Peptide inhibitors, Cancers, 7, 179, 10.3390/cancers7010179

Bidard, 2014, Clinical validity of circulating tumour cells in patients with metastatic breast cancer: a pooled analysis of individual patient data, Lancet Oncol, 15, 406, 10.1016/S1470-2045(14)70069-5

Scher, 2015, Circulating tumor cell biomarker panel as an individual-level surrogate for survival in metastatic castration-resistant prostate cancer, J Clin Oncol, 33, 1348, 10.1200/JCO.2014.55.3487

Diaz, 2012, The molecular evolution of acquired resistance to targeted EGFR blockade in colorectal cancers, Nature, 486, 537, 10.1038/nature11219

Misale, 2012, Emergence of KRAS mutations and acquired resistance to anti-EGFR therapy in colorectal cancer, Nature, 486, 532, 10.1038/nature11156

Misale, 2014, Blockade of EGFR and MEK intercepts heterogeneous mechanisms of acquired resistance to anti-EGFR therapies in colorectal cancer, Sci Transl Med, 6, 224ra26, 10.1126/scitranslmed.3007947

Misale, 2014, Resistance to anti-EGFR therapy in colorectal cancer: from heterogeneity to convergent evolution, Cancer Discov, 4, 1269, 10.1158/2159-8290.CD-14-0462

Van Emburgh, 2014, Acquired resistance to EGFR-targeted therapies in colorectal cancer, Mol Oncol, 8, 1084, 10.1016/j.molonc.2014.05.003

Siravegna, 2015, Clonal evolution and resistance to EGFR blockade in the blood of colorectal cancer patients, Nat Med, 21, 827, 10.1038/nm0715-827b

Mohan, 2014, Changes in colorectal carcinoma genomes under anti-EGFR therapy identified by whole-genome plasma DNA sequencing, PLoS Genet, 10, e1004271, 10.1371/journal.pgen.1004271

Dawson, 2013, Analysis of circulating tumor DNA to monitor metastatic breast cancer, N Engl J Med, 368, 1199, 10.1056/NEJMoa1213261

Madic, 2015, Circulating tumor DNA and circulating tumor cells in metastatic triple negative breast cancer patients, Int J Cancer, 136, 2158, 10.1002/ijc.29265

Heitzer, 2013, Tumor-associated copy number changes in the circulation of patients with prostate cancer identified through whole-genome sequencing, Genome Med, 5, 30, 10.1186/gm434

Azad, 2015, Androgen Receptor Gene Aberrations in Circulating Cell-Free DNA: Biomarkers of Therapeutic Resistance in Castration-Resistant Prostate Cancer, Clin Cancer Res, 21, 2315, 10.1158/1078-0432.CCR-14-2666

Joseph, 2013, A clinically relevant androgen receptor mutation confers resistance to second-generation antiandrogens enzalutamide and ARN-509, Cancer Discov, 3, 1020, 10.1158/2159-8290.CD-13-0226

Romanel, 2015, Plasma AR and abiraterone-resistant prostate cancer, Sci Transl Med, 7, 312re10, 10.1126/scitranslmed.aac9511

Bidard, 2013, Clinical application of circulating tumor cells in breast cancer: overview of the current interventional trials, Cancer Metastasis Rev, 32, 179, 10.1007/s10555-012-9398-0

Smerage, 2014, Circulating tumor cells and response to chemotherapy in metastatic breast cancer: SWOG S0500, J Clin Oncol, 32, 3483, 10.1200/JCO.2014.56.2561

Georgoulias, 2012, Trastuzumab decreases the incidence of clinical relapses in patients with early breast cancer presenting chemotherapy-resistant CK-19mRNA-positive circulating tumor cells: results of a randomized phase II study, Ann Oncol, 23, 1744, 10.1093/annonc/mds020

Douillard, 2014, First-line gefitinib in Caucasian EGFR mutation-positive NSCLC patients: a phase-IV, open-label, single-arm study, Br J Cancer, 110, 55, 10.1038/bjc.2013.721

Korpanty, 2014, Biomarkers That Currently Affect Clinical Practice in Lung Cancer: EGFR, ALK, MET, ROS-1, and KRAS, Frontiers in oncology, 4, 204, 10.3389/fonc.2014.00204

Satelli, 2015, Circulating tumor cell enumeration with a combination of epithelial cell adhesion molecule- and cell-surface vimentin-based methods for monitoring breast cancer therapeutic response, Clin Chem, 61, 259, 10.1373/clinchem.2014.228122

Heidary, 2014, The dynamic range of circulating tumor DNA in metastatic breast cancer, Breast Cancer Res, 16, 421, 10.1186/s13058-014-0421-y

CANCER-ID

Melo, 2015, Glypican-1 identifies cancer exosomes and detects early pancreatic cancer, Nature, 523, 177, 10.1038/nature14581

Hoshino, 2015, Tumour exosome integrins determine organotropic metastasis, Nature, 527, 329, 10.1038/nature15756

Best, 2015, RNA-seq of tumor-educated platelets enables blood-based pan-cancer, multiclass, and molecular pathway cancer diagnostics, Cancer Cell, 28, 666, 10.1016/j.ccell.2015.09.018